The EMJ Podcast: Insights For Healthcare Professionals

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.   Timestamps: 2:14: Memorable career experiences for Claudio   4:20 Biggest breakthrough in MM  5:10 Interest in plasma cell disorders  6:30 A surprising fact about multiple myeloma  7:40 Claudio's top choice for a dinner party guest  10:30 The importance of MRD in haematology  13:00 Monoclonal antibodies and CAR-T therapies  19:00 Current challenges  22:22 Claudio's key EHA and ASCO takeaways  28:30 Claudio's three magic wishes  

In this three-part series, Jonathan Sackier sits down with Professor Zoë Paskins to explore the complexities and advancements in rheumatology and bone health. From her personal journey into the field to innovations in managing osteoporosis and arthritis, Zoë offers compelling insights into the current landscape and future of musculoskeletal care.   Timestamps: 0:25 - What's new in osteoporosis management? 5:05 - Key challenges in addressing gaps in care

In this three-part series, Jonathan Sackier sits down with Professor Zoë Paskins to explore the complexities and advancements in rheumatology and bone health. From her personal journey into the field, to innovations in managing osteoporosis and arthritis, Zoë offers compelling insights into the current landscape and future of musculoskeletal care. Timestamps:     00:00 - Introduction 03:45 - Zoë's start in rheumatology and what keeps her passionate 06:27 - Shared decision-making in rheumatology 12:30 - How should we be screening for osteoporosis?

In this episode of Hema Now, host Jonathan Sackier is joined by Kevin Rouault-Pierre and Onima Chowdhury, to explore the biological mechanisms behind MDS, with a spotlight on SF3B1 mutations. From epigenetic stress to diagnostic strategies, this discussion bridges laboratory research and frontline care.  Timestamps 01:11 – Quickfire Round 07:11 – Haematology Misconceptions  10:56 – Understanding MDS 18:42 – Treating Myeloid Malignancies 23:20 – Epigenetic Mechanisms 28:30 – MDS Treatment Approaches 34:56 – Three Wishes 

Plant-Based Diets In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. 0:19 – The connection between diet and health 4:05 – Organic versus non-organic: does it matter? 4:56 – Plant-based diets and improved erectile function 7:19 – Stigma and undertreatment in men's health 9:14 – Research from the Prostate Cancer Foundation 11:57 – The growing role of lifestyle medicine 14:49 – Glucagon-like peptide-1 (GLP-1) agonists in urological health  

Carbon Emissions in Medicine In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. Timestamps:    0:30 – The carbon footprint of patient travel 2:05 – How climate change affects urological health 5:46 – Practical advice for urologists 7:53 – MRI-targeted prostate biopsies 10:40 – Emissions associated with MRI procedures 

This episode offers insights into the lived experience of patients with Becker Muscular Dystrophy (BMD). Mike Voto, a patient advocate for BMD, shares his story and discusses the personal challenges around diagnosis, disease progression and the impact of living with BMD.

Microplastics In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. Timestamps:   1:01 – Getting into urology 1:52 – Pioneering environmental health in urology 2:28 – Patient perspectives on plastic exposure 4:25 – Microplastics in testicular tissue 7:06 – Plastics are everywhere 9:30 – Immune response to microplastics 10:20 – Microplastics in female genitalia and sanitary product  

In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology.  

In the third episode of our lung cancer miniseries, Jonathan Sackier is joined by Douglas E. Wood, Henry N. Harkins Professor and Chair of Surgery at the University of Washington. A global leader in thoracic oncology, Wood explores the critical role of lung cancer staging, the evolution of screening guidelines, and how surgical innovation is shaping the future of lung cancer treatment. Timestamps: 00:00 – Introduction 02:37 – Career beginnings 07:37 – Career highlights 11:38 – Thoracic oncology guidelines 15:26 – AI and big data 17:17 – Expanding lung cancer screening 19:29 – Robotic surgery 23:38 – Targeted therapies 27:23 – Cancer staging 30:44 – Lung volume reduction surgery 35:10 – Current trials 40:50 – Three wishes for healthcare

In this special episode of Onc Now, host Jonathan Sackier is joined by Lennard Lee, Associate Professor of Cancer Vaccines at the University of Oxford, to explore the promise of personalised cancer vaccines, the power of data science and AI in cancer care, and the national initiatives bringing these innovations to patients. Timestamps 02:01 – Quickfire intro 07:21 – COVID Cancer Programme 11:32 – Cancer vaccine potential 15:56 – Vaccine trial insights 16:58 – Data science and AI 24:10 – Positivity in practice 26:48 – Public health innovation 29:11 – Vaccine hesitancy 33:56 – Final takeaway

Innovations in the treatment of endometriosis and adenomyosis In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Barriers to early endometriosis detection 09:16 – Treating adenomyosis and fertility impact 12:10 – Global health innovation in emerging markets 16:05 – The first uterus transplant

Robotic revolution in reproductive surgery. In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:20 – What's next in gynaecologic robotic surgery? 06:46 – Falcone's pioneering research 16:44 – Three wishes for healthcare

Lydia Scarfò is a Physician Scientist at the B-cell Neoplasia Unit and an Assistant Professor at Università Vita-Salute San Raffaele, Milan, Italy.   She is involved in both clinical and pre-clinical studies, including being a co-investigator in over 20 clinical trials in haematological malignancies, including chronic lymphocytic leukaemia.  Timestamps:  0:00 – Introduction  1:14 – Quickfire questions  7:31 – Haematology inspiration  9:08 – STIL loss  11:42 – Splenic marginal zone lymphoma  13:03 – Novel targeted therapies for chronic lymphocytic leukaemia  17:35 – Covalent BTK inhibitors   19:30 – Chemo-free approach for hairy cell leukaemia  22:20 – Recent advances, challenges, and opportunities  25:58 – Three wishes 

Global Perspectives and Leadership in Gynaecology In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Comparing gynaecology globally 03:20 – The evolution of endometriosis research 05:30 – Breakthroughs and hopes for a cure

In this episode, the host Saranya Ravindran speaks with Tommaso Falcone about transformative developments in reproductive health, including the evolution of endometriosis research, the promise of robotic surgery, and the global expansion of gynaecologic care. From debunking myths about fertility to reflecting on cross-continental medical practice, this episode explores the future of women's health through the eyes of a pioneering clinician and researcher. Timestamps: 00:00 – Introduction 01:05 – Quickfire round 05:12 – ‘Yes or no' segment

This episode offers expert insights Dr. Aravindhan Veerapandiyan, MD. Exploring Becker Muscular Dystrophy (BMD), covering early signs, diagnostic challenges, disease progression, and current management approaches. It also explores care transitions, multidisciplinary involvement, and unmet needs in the BMD care landscape.

In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy. Baldwin reflects on national screening programmes, groundbreaking trials, and how AI, big data, and evidence-based guidelines are reshaping lung cancer care. Timestamps: 00:00 – Introduction 03:17 – Key takeaways from the UKLS trial 11:10 – Boosting participation in screening studies 17:04 – The Targeted Lung Health Check programme 23:30 – Understanding large datasets in lung cancer epidemiology 32:44 – AI and big data in lung cancer imaging 41:43 – Shaping national guidelines 47:47 – Are we doing enough to prevent lung cancer? 53:06 – Baldwin's three wishes for healthcare

In the second part of this special episode of Onc Now, Jonathan Sackier continues his thrilling conversation with Bradley Monk, a leading gynaecologic oncologist, with an in-depth discussion of the DUO-E trial, Monk's most impactful Society of Gynecologic Oncology (SGO) insights, and the integration of AI into the clinic. Timestamps:  00:00 – Introduction  00:40 – Quickfire questions  06:19 – Inspiration  08:31 – Molecular basis of cancer treatment  12:12 – DUO-E trial design  14:12 – Barriers to 4-drug regimen approval and access  20:01 – Most impactful SGO insights  21:10 – AI integration  24:03 – Three wishes  26:30 – Outro 

In the third and final episode of our miniseries on infectious disease diagnostics, Jonathan sits down with global diagnostics leader Rosanna Peeling, Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine. Together, they explore the life-saving role of diagnostics in global health, from battling STDs to confronting COVID-19, and examine how equitable access, social innovation, and regulatory reform can transform disease control and pandemic preparedness.   Timestamps: 00:00 – Introduction 06:09 – Rosanna's interest in microbiology 08:12 – The IDC's work 10:52 – Funding for diagnostics 13:30 – Diagnostic testing in low-resource settings 18:21 – Chlamydia research 24:19 – Regulatory approval challenges 29:35 – Social innovation 34:08 – Clinician adaptation 37:10 – Current diagnostic innovations 40:30 – Rosana's three wishes for healthcare

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

In this episode, Jonathan Sackier kicks off a special miniseries on lung cancer with Haval Balata, Consultant Respiratory Physician at Manchester University NHS Foundation Trust. From the Manchester Lung Health Check to robotic bronchoscopy, Balata shares insights into pioneering early detection efforts, the challenge of public misconceptions, and innovations reshaping lung cancer screening and diagnosis. Timestamps: 03:12 – Inspiration to specialise 04:09 – Early diagnosis barriers 08:02 – Manchester Lung Health Check 14:10 – Robot-assisted bronchoscopy 19:24 – Public misconceptions 28:57 – Risk stratification & follow-up 34:24 – Innovations in early detection 37:10 – Hopes for the future 41:22 – Three healthcare wishes

In this two-part series host Jonathan Sackier is joined by Bradley Monk, a pioneering figure in gynaecologic oncology. In Part 1, they discuss key updates from the European Society of Gynaecological Oncology (ESGO) Congress, including the updated ESGO-ESTRO-ESP endometrial cancer guidelines and the latest results from the KEYLYNK-001 study in ovarian cancer. With reflections from his three-decade career, Monk provides actionable takeaways for clinicians and researchers alike. Stay tuned for Part 2, where they delve into insights from SGO 2025.  Timestamps:  00:00 - Quickfire questions 04:55 - Career milestones 07:10 - ESGO 2025 standout sessions 09:52 - KEYLYNK-001 trial & takeaways 13:52 - New endometrial cancer staging   

In this bonus episode, join EMJ host Dr Hannah Moir as she speaks with our two urological experts, Dr Todd Linsenmeyer and Dr Chris Harding. They discuss recent advances in day-to-day technologies for intermittent catheterisation, covering innovations and advancements in catheter technology aimed at improving the user experience.

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamps: 1:12 – A typical consultation 7:50 – Advice for clinicians

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamps: 0:14 – The power of hope for patients 1:08 – Opening her own practice  

In this three-part series, Jonathan Sackier sits down with Isabelle Amigues, rheumatologist and founder of UnabridgedMD, a direct rheumatology practice in Denver, Colorado, USA. Together, they discuss the importance of hope in patient care and the inspiration behind starting her own practice. Timestamp: 2:27 – The origins of ‘Hope Driven by Science'

In this episode of Hema Now, host Jonathan Sackier is joined by Paolo Gallipoli, Clinical Reader at the Centre for Haemato-Oncology at Barts Cancer Institute, to break down the biology, onset, and treatment of myeloid leukaemias. They detail common misconceptions about myeloid leukaemias, explain the differences between chronic myeloid leukaemia and acute myeloid leukaemia, and discuss Gallipoli's own research in the field, with a view towards future developments.  Timestamps  01:34 – Quickfire questions  06:55 – Potential careers  08:43 – Common misconceptions  11:34 – Best advice received  13:43 – Adaptive metabolic changes  16:45 – Chronic myeloid leukaemia vs acute myeloid leukaemia  19:20 – Recent publication  22:55 – Clonal hematopoiesis    27:13 – Treatment obstacles  29:18 – Future developments  31:01 – Gallipoli's three wishes 

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 01:47 – Interstitial Lung Disease 08:25 – Evolution of Rheumatology 11:39 – Wishes for Healthcare

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care 01:49 – Polymyalgia Rheumatica 05:59 – Vascular Ultrasound 09:11 – Immune Ageing

In this three-part series, Jonathan Sackier sits down with Richard Conway, rheumatologist, researcher, and educator. Together, they delve into cutting-edge insights on polymyalgia rheumatica, immune ageing, and the future of rheumatology care. 00:22 – Mortality Patterns 08:57 – JAK Inhibitors

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease. Timestamps: 00:00 – Healthtech innovation 03:02 – Biohacking's future 09:20 – Three healthcare wishes   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps: 00:00 – Resilience Health's impact 04:30 – Gut–brain connection 12:00 – Immune optimisation   

In this three-part series, Jonathan Sackier is joined by Rini Chatterjee, clinician, longevity expert, and Founder of Resilience Health. Together, they explore how functional medicine, biohacking, and evolutionary biology can be used to transform modern health care, improve health span, and prevent chronic disease.  Timestamps:  02:00 – Career evolution 06:45 – Holistic medicine explained 

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

This is a non-promotional podcast funded and developed by AbbVie for healthcare professionals only. The content of this podcast is correct at the time of recording, which is December 2024. The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the view of AbbVie or EMJ If you are listening to this podcast through a podcast app, please note that any advertisements you may hear are not affiliated with this podcast or AbbVie in any way. To stop receiving podcast notifications, please unsubscribe from this series in your podcast player. The Post-Stroke Spasticity Classification System was created and funded by AbbVie with the assistance of a group of international experts in the field of Post-Stroke Spasticity, utilising both published risk factors and their own clinical experience. BONT-AA-00049-MC April 2025

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.  Timestamps:    00:17 – Digital health equity  06:00 – Podcasts in medicine  07:59 – Three cardiology wishes 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:  02:06 – Skiing & heart  04:02 – Blix award impact  07:51 – Heart failure biomarkers 

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Janice Walshe, Consultant Medical Oncologist at St Vincent's University Hospital, Dublin, Ireland. They explore the economic realities of cancer diagnostics, fertility preservation in patients with breast cancer, and the impact of international collaboration on the future of clinical trials.  Timestamps:    00:00 – Introduction  03:25 – Economic disparities and oncology care in Ireland  07:20 – Neoadjuvant therapy for HER2-positive breast cancer  10:13 – Spotlight on invasive lobular carcinoma  12:36 – Fertility preservation in breast cancer  15:20 – Menopause after cancer  19:09 – The latest clinical trials in Ireland  21:50 – International trials and research projects  23:50 – Walshe's three wishes for healthcare 

In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

In the second episode of our miniseries on infectious disease diagnostics, Jonathan is joined by molecular epidemiologist Rodney Rohde, Regents' Professor at Texas State University, USA. Together, they explore diagnostic innovations in the fight against antimicrobial resistance, gaps in zoonotic disease detection, and the persistent challenge of vaccine hesitancy. Timestamps: 00:00 – Introduction 01:45 – Breakthroughs in molecular diagnostics 08:30 – Diagnostic tools to combat superbugs 14:18 – Can bacteriophages replace antibiotics? 19:04 – Controlling rabies and hantavirus 28:33 – Diagnostic successes and failures from COVID-19 35:22 – How do we address vaccine hesitancy? 44:10 – Preparing for the next pandemic 47:03 – Rohde's three wishes for healthcare

In this episode, Jonathan Sackier is joined by Philip Hamann, Consultant Rheumatologist at North Bristol NHS Trust, UK. Known for his engaging TEDx talks and innovative work with AI-driven healthcare apps, Hamann discusses how big data, personalised medicine, and a holistic approach are revolutionising care for patients with rheumatoid arthritis.  Timestamps:  00:00 – Introduction   01:01 – Using humour to communicate science   06:02 – ‘Living with Rheumatoid Arthritis': Hamann's award-winning app  14:43 – The cost of personalised medicine  19:07 – Real-world use of the app  26:05 – Importance of real-time data in rheumatology  33:10 – What does holistic care really mean?  40:07 – Hamann's three wishes for healthcare